Article citationsMore>>

S. D. Wiviott, D. Trenk and A. L. Frelinger, “Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 trial,” Circulation, Vol. 116, 2007, pp. 2923-2932.

has been cited by the following article:

• TITLE: Rationale and Role of High Loading Dose Clopidogrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

  AUTHORS: Sam T. Mathew, Gayathri Devi S, Prasanth V. V, Vinod B

  KEYWORDS: Clopidogrel; Antiplatelet Therapy; Percutaneous Coronary Intervention

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.3 No.4, October 26, 2012

  ABSTRACT: Antiplatelet therapy, which reduces platelet activation and aggregation, is the corner stone of treatment for patients undergoing percutaneous coronary intervention (PCI). Clopidogrel is an established oral antiplatelet medication of thienopyridine class, which inhibits blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease. Many studies have revealed that high loading dose clopidogrel in patients undergoing PCI. This review article investigates the rationale and role of high loading dose clopidogrel in patients undergoing PCI.